Drug Database
NI

nitroglycerin (Millisrol Tape)

✓ Approved

Nippon Kayaku Co.,Ltd. · Small Molecule · Small Molecule

What is nitroglycerin?

nitroglycerin is a small molecule developed by Nippon Kayaku Co.,Ltd.. It is approved for therapeutic indications via transdermal.

Drug Profile

Brand NamesMillisrol Tape
CompanyNippon Kayaku Co.,Ltd.
Drug ClassSmall Molecule
RouteTransdermal
StatusApproved

Therapeutic Indications

nitroglycerin is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Cardiac disordersAngina pectoris✓ Approved

Related Research Articles

PubMedCardiology in the young2026-10-16

Reversible atrioventricular block associated with transdermal fentanyl use: a paediatric case with non-Hodgkin lymphoma.

Çevlik Burcu B, Tunca Sahin Gülhan G, Dönmez Mehmet Cemal MC, Özturk Erkut E

Pain is a common and significant clinical problem in childhood cancers, arising both from the disease itself and from administered treatments. Although pain control is primarily achieved with routine analgesics, this may be insufficient in chronic or progressive stages of the disease. In such cases, treatment with potent analgesics, such as opioid derivatives, comes into play. Transdermal fentanyl is widely preferred in paediatric oncology practice due to its ease of administration and effective analgesic properties. The most common adverse effects of opioids include tolerance, nausea, vomiting, and constipation. Drugs known to cause atrioventricular block include beta-blockers, digoxin, calcium channel blockers, certain immunosuppressive agents, and many antiarrhythmic drugs. Drug-induced atrioventricular block is generally reversible and resolves after discontinuation of the offending agent. In this report, we present a paediatric patient with common variable immunodeficiency and non-Hodgkin lymphoma who developed first-degree atrioventricular block along with second-degree type I (Wenckebach) and type II atrioventricular block during transdermal fentanyl therapy. Given the rarity of this adverse effect, we believe this case contributes to the literature by highlighting a potential conduction system complication associated with opioid use.

PubMedClimacteric : the journal of the International Menopause Society2026-10-16

Effects of testosterone on exercise capacity in postmenopausal women with stage B heart failure.

Grant Julia J, Alexander Sarah E SE, Marwick Thomas H TH, Islam Rakibul M RM et al.

Asymptomatic individuals with stage B heart failure (HF) often have reduced exercise capacity. As exogenous testosterone may have favorable skeletal muscle and vasculature effects, this study investigated whether transdermal testosterone improves exercise capacity in women with stage B HF. In this single-center, double-blind, randomized, placebo-controlled crossover trial involving women aged ≥55 years with stage B HF (defined as cardiac remodeling and/or diastolic dysfunction) and reduced exercise capacity (<100% age-predicted peak oxygen uptake V˙O2peak]), participants were randomly allocated to transdermal testosterone 5 mg/day or identical placebo for 4 months with cross-over after a 4-week washout. The primary outcome was change in V˙O2peak. Secondary outcomes included changes to cardiac structure and function assessed by echocardiography and cardiac magnetic resonance imaging, and subjective quality of life. Thirty-eight participants (median age 72 years, range 60-80 years; median body mass index 33.2 kg/m2 [P25-P75 28.7-35.9 kg/m2]) completed the study. Testosterone treatment increased circulating serum testosterone concentrations and was well tolerated, with no adverse treatment-related events. Testosterone treatment had no significant effect on V˙O2peak (β = -0.05, 95% confidence interval = -0.74, 0.65, p = 0.897), cardiac structure or indices of cardiac function, or quality of life. Transdermal testosterone treatment did not improve exercise capacity in postmenopausal women with stage B HF.

PubMedPolymers2026-10-16

Polyvinyl Alcohol-Coated Polycaprolactone Microneedles as Polymeric Microdevices for Transdermal Antigen Delivery and Immune Activation.

Teixeira Aline F AF, Kochi Leandro T LT, De La Via Reis Ana Carola AC, Rojas Jose E JE et al.

Conventional needle-and-syringe vaccination is associated with pain, needle-related anxiety, the need for trained personnel, and logistical challenges related to vaccine distribution and storage. Microneedle (MN) technology has emerged as a minimally invasive strategy for transdermal delivery and as a platform for functional polymeric microdevices. In this study, polycaprolactone (PCL) microneedles coated with hydrophilic polymers were evaluated as a model platform for antigen delivery. Ex vivo assays using porcine ear skin were explored as a preliminary approach to assess antigen transport from polymer-coated PCL microneedles. However, antigen-specific quantification in the receptor compartment was limited by the lack of specificity of absorbance-based measurements in this biological matrix. Scanning electron microscopy (SEM) showed that PVA coating partially altered microneedle tip morphology, whereas optical coherence tomography (OCT) and optical microscopy confirmed that PVA20%-PCL-MNs maintained the ability to insert into porcine skin and generate visible insertion sites. Mechanical compression testing further showed that polymer-coated PCL-MNs maintained resistance to axial deformation under the tested conditions. PVA20%-PCL-MNs were also non-toxic and maintained high HEK293T cell viability after 24 h. Based on their preserved insertion capacity, mechanical robustness, ability to support DNP-KLH permeation, and preliminary cytocompatibility, PVA20%-PCL-MNs were evaluated in BALB/c mice using a two-dose prime-boost regimen. Although intraperitoneal immunization induced higher IgG levels, transdermal immunization with PVA20%-PCL-MNs promoted booster-dependent antigen-specific IgG responses. IgG2a/IgG1 ratio analysis indicated a predominantly IgG1-biased humoral profile, and splenocytes from mice immunized with PVA20%-PCL-MNs produced detectable levels of IFN-γ and IL-10 after in vitro stimulation. Together, these findings support PVA-coated PCL microneedles as a proof-of-concept polymeric microdevice platform for minimally invasive antigen delivery and immunogenicity assessment.

PubMedInternational journal of molecular sciences2026-10-16

Microneedles for Chronic Refractory Wounds: A Review of Dynamic Regulation Strategies and Therapeutic Applications.

Liu Quanying Q, Xu Yang Y, Li Wenfeng W, Shi Chunmeng C

Chronic refractory wounds (CRWs), characterized by delayed healing due to disrupted phases of hemostasis, inflammation, proliferation, and remodeling, pose significant clinical challenges with diverse etiologies such as diabetic ulcers and radiation-induced ulcers. Traditional therapies like debridement and skin flap transplantation face limitations. Microneedle technology has emerged as a promising approach, enabling painless transdermal drug delivery to the dermis while enhancing bioavailability and enabling microenvironment-responsive interventions. In this context, this review highlights advancements in microneedle design, emphasizing material selection and structural innovations tailored for CRW management, and systematically elucidates the mechanisms of action and applications of microneedles for phased regulation of CRW healing in response to the pathologic characteristics of wounds-hemostatic, inflammation regulation, angiogenesis and remodeling stage-in terms of prevention, intervention, and wound monitoring, thereby providing significant reference value for the design and clinical application of microneedles in chronic refractory wounds.

PubMedMolecules (Basel, Switzerland)2026-10-16

Reimagining Cannabidiol Delivery Through Carbon Nanodots.

Ibrahim Iddrisu I, Lawrence Kelci K, Forte Othreniel Angel OA, Naidu Navitri Chandra NC et al.

Cannabidiol (CBD) is a highly lipophilic phytocannabinoid whose low aqueous solubility, variable oral absorption, extensive first-pass metabolism, and chemical instability motivate advanced delivery strategies. Carbon nanodots (CNDs) have tunable surface chemistry and photoluminescence and have been investigated as carriers for multiple therapeutic cargos. This review critically evaluates whether the literature supports a specific CBD-CND delivery advantage. A structured narrative search of PubMed and targeted publisher websites was conducted. Evidence was classified as direct CBD-CND evidence, indirect CND-platform evidence, or indirect CBD-nanoformulation evidence. No direct study was identified that characterized CBD loading on CNDs and then demonstrated release, pharmacokinetics, safety, or therapeutic efficacy. Existing support is therefore indirect: CNDs can carry other drugs, whereas lipid, polymeric, micellar, and transdermal systems can improve selected CBD formulation or preclinical endpoints. Consequently, improved solubility, targeting, lower toxicity, enhanced bioavailability, and therapeutic synergy remain hypotheses for CBD-CND systems. The review retains a broad discussion of possible applications while clearly separating demonstrated evidence from proposed uses and defining the analytical, comparative, pharmacokinetic, biodistribution, and toxicological studies needed to validate the platform.

PubMedBiomaterials science2026-10-15

Correction: Mechanical stress-driven conformational compaction of polydeoxyribonucleotide for enhanced transdermal regenerative therapy.

Jeon Saetbyeol S, Lee Jung Im JI, Shim Sung Bo SB, Kim Chul Hwan CH et al.

Correction for 'Mechanical stress-driven conformational compaction of polydeoxyribonucleotide for enhanced transdermal regenerative therapy' by Saetbyeol Jeon et al., Biomater. Sci., 2026, 14, 3995-4005, https://doi.org/10.1039/d6bm00713a.

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about nitroglycerin